Compare Crispr Therapeutics AG (CRSP) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs NRG Energy Inc — how do they compare? Crispr Therapeutics AG trades at $54.1 (market cap $5.23B), while NRG Energy Inc trades at $121.78 (market cap $24.83B). The key difference: NRG Energy Inc is far larger — about 4.7× Crispr Therapeutics AG's market cap, and NRG Energy Inc pays a 1.61% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | NRG | |
|---|---|---|
Market Cap | $5.23B | $24.83B |
Sector | Health | Utilities |
52-Week High | $76.78 | $184.03 |
52-Week Low | $44.34 | $117.04 |
Enterprise Value | $3.65B | $48.79B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
NRG Energy trades at $120.97, up 1.73% today, with a bearish technical signal despite oversold RSI levels near support at $119. The company reported Q2 2026 EPS of $1.49, missing estimates of $1.69, but revenue grew 11% year-over-year, driven by cost controls and a strategic 1.2 GW Texas data-center power project. Fundamentals show a P/E of 30.76 and ROE of 26.77%, though net margin is thin at 2.56%.
Outlook is mixed: analyst consensus is bullish with a $207.83 price target (69% buy ratings), citing growth from data-center demand, but risks include rising interest costs, high leverage (debt-to-assets at 56.42% in 2025), and earnings misses. The stock offers a 1.6% dividend yield, but investors face volatility from execution risks in expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
